Chromate(2-), [3-[4,5-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-3-methyl-5-oxo-1H-pyrazol-1-yl]benzenesulfonato(3-)][2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)]-, sodium

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1974

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Basic data given, acceptable for assessment

Cross-reference

Cross-reference 1

Reason / purpose for cross-reference:

reference to same study

Cross-reference 2

Reason / purpose for cross-reference:

reference to other study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1974

Report date:

1974

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Principles of method if other than guideline:

Pre-guideline test according to internal SOP. Test procedure is in line with OECD 401 established later in the 1980ies.

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Chromate(2-), [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-2-hydroxy-5-nitrobenzenesulfonato(3-)]-, disodium

EC Number:

260-394-7

EC Name:

Chromate(2-), [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-2-hydroxy-5-nitrobenzenesulfonato(3-)]-, disodium

Cas Number:

56819-40-0

Molecular formula:

C32H21CrN10O11S.2Na

IUPAC Name:

Chromate(2-), [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-2-hydroxy-5-nitrobenzenesulfonato(3-)]-, disodium

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Details on test material:

None

Test animals

Species:

rat

Strain:

other: CFY

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: 95 to 117g
- Fasting period before study:starved overnight

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

VEHICLE
- Concentration in vehicle:16.7ml/kg bodyweight

MAXIMUM DOSE VOLUME APPLIED:5g/kg bodyweight

Doses:

5g/kg bodyweight

No. of animals per sex per dose:

Ten rats (five males and five females)

Control animals:

yes

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,mortality

Statistics:

None

Results and discussion

Preliminary study:

None

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 5 000 mg/kg bw

Based on:

test mat.

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 850 mg/kg bw

Based on:

act. ingr.

Mortality:

There were no mortalities occuring throughout the study period.

Clinical signs:

Signs of reaction to treatment, observed shortly after treatment, included lethargy, pilo-erection, diuresis and diarrhoea. The urine and faeces of all rats were stained orange.

Body weight:

Recovery of all animals, as judged by external appearance and behaviour, was apparently complete two days after treatment. This observation was substantiated by normal bodyweight increases compared with controls.

Gross pathology:

No abnormalities recorded.

Other findings:

None

Any other information on results incl. tables

None

Applicant's summary and conclusion

Interpretation of results:

other: not classified following Regulation 1272/2008

Conclusions:

The acute median lethal oral close (LD50) to rats of the substance was found to be greater than 5000 mg/kg bodyweight.

Executive summary:

Test was conducted to assess the acute toxicity od test substance following an internal standard acute method.

Ten rats (5 male and 5 female) weighing 95 to 117g were dosed at a 5g/kg bw and observed for 14 days.

No mortality was observed at the end of the 14-day observation period. But signs of reaction to treatment included lethargy, pilo-erection, diuresis and diarrhoea. The urine and faeces of all rats were stained orange. All the animals recovered, showed normal bodyweight increase in comparison to controls and gross pathology was normal.

The acute median lethal oral toxicity (LD50) to rats of was found to be greater than 5000 mg/kg bodyweight. The acute median lethal toxicity based on the active ingredient was calculated to be >2850 mg/kg bw.